This study demonstrates experimentally that pre-stroke pharmacological targeting of obesity by GLP-1R and NPY2R activation in type 2 diabetes enhances stroke recovery, without effects additional to weight loss mediated by the treatments. This evidence concerns the gene GLP1R and stroke disorder.